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Abstract
Introduction: Recent studies reported that human IgG antibodies are susceptible to specific proteolytic cleavage in
their lower hinge region, and the hinge cleavage results in a loss of Fc-mediated effector functions. Trastuzumab is a
humanized IgG1 therapeutic monoclonal antibody for the treatment of HER2-overexpressing breast cancers, and its
mechanisms of action consist of inhibition of HER2 signaling and Fc-mediated antibody-dependent cellular cytotoxicity
(ADCC). The objective of this study is to investigate the potential effect of proteinase hinge cleavage on the efficacy of
trastuzumab using both a breast cancer cell culture method and an in vivo mouse xenograft tumor model.
Methods: Trastuzumab antibody was incubated with a panel of human matrix metalloproteinases, and proteolytic
cleavage in the lower hinge region was detected using both western blotting and mass spectrometry. Single hinge
cleaved trastuzumab (scIgG-T) was purified and evaluated for its ability to mediate ADCC and inhibition of breast
cancer cell proliferation in vitro as well as anti-tumor efficacy in the mouse xenograft tumor model. Infiltrated
immune cells were detected in tumor tissues by immunohistochemistry.
Results: scIgG-T retains HER2 antigen binding activity and inhibits HER2-mediated downstream signaling and cell
proliferation in vitro when compared with the intact trastuzumab. However, scIgG-T lost Fc-mediated ADCC activity
in vitro, and had significantly reduced anti-tumor efficacy in a mouse xenograft tumor model.
Immunohistochemistry showed reduced immune cell infiltration in tumor tissues treated with scIgG-T when
compared with those treated with the intact trastuzumab, which is consistent with the decreased ADCC mediated
by scIgG-T in vitro.
Conclusion: Trastuzumab can be cleaved by matrix metalloproteinases within the lower hinge. scIgG-T exhibited a
significantly reduced anti-tumor efficacy in vivo due to the weakened immune effector function such as ADCC. The
results suggest that the lower hinge cleavage of trastuzumab can occur in the tumor microenvironment where
matrix metalloproteinases often have high levels of expression and scIgG-T might compromise its anti-tumor
efficacy in the clinic. However, further studies are needed to validate these hypotheses in the clinical setting.
Introduction
Trastuzumab is a humanized IgG1 monoclonal antibody
for the treatment of primary and metastatic breast can-
cers that overexpress HER2 [1]. Both antigen engagement
by the Fab region, which results in HER2 signaling inhi-
bition, as well as induction of immune effector functions
such as antibody-dependent cellular cytotoxicity (ADCC)
mediated by the Fc region play important roles in the
mechanisms of action of trastuzumab [2-4]. Despite the
clinical success of trastuzumab in treating high HER2
breast cancers, primary and acquired resistance to the
therapy is widespread in the clinic [5]. Previous studies
on resistance to trastuzumab have focused in large part
on cell signaling escape mechanisms. These studies have
included loss of phosphatase and tensin homolog func-
tion, gain of function mutations in signaling molecules
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such as phosphatidylinositol 3-kinase and protein kinase
B (AKT) [6,7], activation of HER family member recep-
tors epidermal growth factor receptor and HER3 [8], and
upregulation of other receptor tyrosine kinases such as
insulin-like growth factor 1 receptor [9], hepatocyte
growth factor receptor (cMET) [10], and ephrin-A family
tyrosine kinase receptor 2 [11].
IgG antibody is known to be susceptible to specific clea-
vage within the hinge region by proteinases in vitro
[12,13]. Extracellular proteinases secreted by certain
human bacterial pathogens can cleave human IgGs within
the lower hinge region, and these proteinases are sug-
gested to function as virulence factors by evading the host
immune response to bacterial infections [14-17]. Recent
reports have also demonstrated that certain human matrix
metalloproteinases (MMP-3, MMP-7, MMP-9, MMP-12
and MMP-13) can catalyze a single-strand cleavage of
human IgG1 antibodies in the lower hinge region in vitro
[15,18], although the rate of cleavage varies among the dif-
ferent MMPs. Purified single-cleaved IgG1 antibodies were
shown to have substantially depressed immune effector
functions such as ADCC and complement-dependent
cytotoxicity [18-20]. The loss of antibody Fc effector func-
tion was correlated with a decreased binding to Fcg recep-
tors that are expressed on immune effector cells such as
natural killer (NK) cells and monocytes [18,21]. Since
ADCC is considered one of the key mechanisms of action
for trastuzumab [3,22-26], factors that compromise
Fc-mediated immune functions of trastuzumab are
expected to decrease its efficacy.
The study described in this report investigated the
impact of trastuzumab hinge cleavage on its anti-HER2
signaling function and anti-tumor efficacy in vitro and
in vivo. The results demonstrated that single cleavage of
trastuzumab within the lower hinge severely impaired
Fc-mediated immune effector cell function in vitro and
resulted in significantly reduced anti-cancer efficacy
in vivo. These findings underscore the potential effects
of proteolytic hinge cleavage of trastuzumab and other
therapeutic antibodies in the tumor microenvironment
by compromising their clinical efficacy.
Materials and methods
Enzymes, antibodies and cell lines
Trastuzumab was purchased from a specialty pharmacy.
Single hinge cleaved trastuzumab (scIgG-T) was prepared
by enzymatic digestion with a bacterial proteinase, IgG-
degrading enzyme S (IdeS), as previously described
[15,18]. Recombinant IdeS was expressed in Escherichia
coli and purchased from Genovis AB (Lund, Sweden).
The isotype control monoclonal antibody (human IgG1)
was expressed at Janssen R&D, LLC (Radnor, PA, USA).
The cancer cell lines SKOV-3 and BT474 were obtained
from American Type Culture Collection (Manassas, VA,
USA), and were grown in RPMI 1640 media supplemen-
ted with 10% fetal bovine serum, 2 mM glutamine, 50
units/ml penicillin, and 50 µg/ml streptomycin in an
incubator with 5% CO2 at 37°C. Antibodies for total
HER2, pHER2 (Y1248), pHER3 (Y1289), pEGFR (Y1068),
pAKT (S473), and pErk1/2 (T202/Y204) were purchased
from Epitomics (Burlingame, CA, USA).
Capillary gel electrophoresis
The method used for antibody hinge cleavage and gel
analysis were reported previously [15]. Briefly, trastuzu-
mab was subjected to proteolysis by recombinant human
MMPs or the bacterial protease IdeS in Tris-buffered sal-
ine plus calcium chloride. Electrophoresis separation was
performed using an Agilent 2100 microfluidics-based
Bioanalyzer (Agilent Technologies, Santa Clara, CA,
USA). Proteins were applied at 1 mg/ml in Tris-buffered
saline and run on Agilent 230 chips following the manu-
facturer’s protocol [27]. Trastuzumab digests were run
under nonreducing conditions to best visualize the
single-cleaved products.
Flow cytometry
Binding of trastuzumab and scIgG-T on HER2-expres-
sing breast cancer cells was measured using a Guava
easyCyte HT instrument based on the manufacturer’s
instructions (Millipore, Danvers, MA, USA). Briefly,
5×105 cells were dispensed in 100 µl aliquots and trastu-
zumab as primary antibody was added for 1 hour at 25°C,
followed by the addition of phycoerythrin-conjugated
anti-human-Fc (Jackson ImmuneResearch Laboratories,
Inc., West Grove, PA, USA). After washing with PBS buf-
fer, the cells were analyzed for fluorescence intensity and
human isotype IgG1 antibody was used as the reference
sample control.
Fcg receptor binding assays
Binding of Fcg receptors with antibodies was determined
by ELISA as reported previously [28]. Fcg receptors were
from R&D Systems (Minneapolis, MN, USA). The fluor-
escence signal was detected at excitation 340 nm and
emission 460 nm using a plate reader (Molecular Devices,
Sunnyvale, CA, USA).
Cell lysate preparation from tumor tissues
Tumor tissues from mouse xenograft studies or breast
cancer patients were homogenized using gentle MACS
(Miltenyi Biotec, Bergisch Gladbach, Germany) according
to the manufacturer’s procedure in a cell lysis buffer in
the presence of proteinase inhibitor cocktails (Calbio-
chem, San Diego, CA, USA). Trastuzumab was affinity
enriched from the tissue lysate using HER2 extracellular
domain protein (Sino Biologicals, Beijing, China) and
used for SDS-PAGE and western blotting analysis.
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Western blotting
Cell lysates prepared from cell culture or tumor tissues
were subjected to SDS-PAGE separation. Gels were
either stained with Coomassie blue (Bio-Rad, CA, USA)
or transferred to a polyvinylidene fluoride membrane by
standard procedures. Membranes were blotted using a
goat-anti-human Fc-horseradish peroxidase (Sigma-
Aldrich, St. Louis, MO, USA) and images were detected
with FluorChem M imager (Cell BioSciences, Santa
Clara, CA, USA) using enhanced chemiluminescence
substrate (GE Healthcare, Piscataway, NJ, USA).
Antibody-dependent cellular cytotoxicity assay
ADCC activities were assayed as described previously
[29] using the xCELLigence instrument (Roche, Man-
nheim, Germany). Briefly, the high HER2 expression
cancer cell line SKOV-3 was seeded in E-plate 96
(ACEA Biosciences, Inc., San Diego, CA, USA), followed
by the addition of human peripheral blood mononuclear
cells (PBMC) cells as immune effector cells. Human
PBMC were isolated from fresh blood samples collected
from consented healthy volunteers using procedures
reported previously [18]. Antibodies were added in
three-fold titration starting from 5 µg/ml, and the cell
index (cell growth) was monitored continuously for
2 days. Cancer cells with PBMC only were used as the
control group and the ratio of effector cells to target
cells was 50:1. The cell index recorded after 24 hours of
treatment with trastuzumab and scIgG-T was used to
calculate the percentage of cell lysis using the formula:
(
Cell index of control group − cell index of treatment group) /cell index of control group×100
Each treatment contains three replicates and the stan-
dard deviation is shown in the plots.
Cell proliferation assay
Inhibition of breast cancer cell proliferation by trastuzu-
mab and scIgG-T was measured based on a reported pro-
cedure [29]. Briefly, BT474 cells (5,000 cells/well) were
seeded in a 96-well plate and cultured overnight in RPMI
medium with 10% fetal bovine serum at 37°C and 5%
CO2. Treatment antibodies were added into the cell cul-
ture in a series of concentrations (0 to 10 µg/ml) and con-
tinued incubation for 72 hours. Alamar Blue (Invitrogen,
Carlsbad, CA, USA) was added according to the manufac-
turer’s instructions and fluorescence signal was read using
a SpectraMax M4 plate reader (Molecular Devices) using
excitation at 535 nm and emission at 590 nm.
Mouse xenograft tumor model
Mouse xenograft studies were carried out in accordance
with the animal care and use guidelines and the proto-
col was approved by the Animal Welfare Committee of
the University of Texas Medical School at Houston.
HER2-overexpressing BT474 breast cancer cells were
used in the xenograft model as previously described
[29]. Immunodeficient nu/nu mice from a homogeneous
BALB/c background were from Charles River Labora-
tories (Wilmington, MA, USA). When tumors reached
50 to 100 mm3, mice were randomized into treatment
groups with five mice per group. Antibodies were admi-
nistered weekly intraperitoneally at 5 mg/kg dosing level
for 6 weeks. Tumor size was measured and recorded
every 3 or 4 days using a Vernier scale caliper. Tumor
tissue and sera were collected and stored at -80°C until
analysis.
Immunohistochemistry
Xenograft tumor tissues were excised freshly and fixed in
4% paraformaldehyde and embedded in paraffin. Serial 4-
μm thick sections were made for staining. Anti-mouse
integrin aM/CD11b and F4/80 antibodies (R&D Systems)
were applied as primary antibody, and positive staining
was visualized using a three-step staining procedure with
an Elite ABC kit (Vector Laboratories, Peterborough,
UK) and counterstained with hematoxylin (Vector
Laboratories). Six tumor tissue sections (n = 6) were
made from each treatment group and the tissue slides
were viewed using Nikon Eclipse E200 microscopy and
the entire tumor sections were scanned at 10× (magnifi-
cation = 10×10) to identify all positive stained cells.
Representative images from each treatment group were
taken under ×40 magnification. The average number of
immune cell infiltration per tumor slide under ×40 mag-
nification was plotted for each treatment groups and
standard error was calculated among the six tissue slides.
Mass spectrometry analysis
Mass spectral analyses were performed in the Transla-
tional Proteomics Core at University of Texas Health
Science Center at Houston. Protein bands were excised
and in-gel digestion was performed as previously described
[30]. Tryptic digested proteins were taken to dryness in a
Thermo SpeedVac and dissolved in 20 µl of 2% acetoni-
trile, 0.1% formic acid (solvent A). Aliquots of the digest
were analyzed by liquid chromatography/mass spectrome-
try (MS)/MS on an Agilent 6538 UHD Accurate-Mass
Quadrupole Time-of-Flight mass spectrometer equipped
with an Agilent 1260 nanoLC system. The reverse-phase
chromatography was performed on an Agilent High Capa-
city Chip (143 mm) using solvent A as the initial mobile
phase and varying percentages of solvent B (90% acetoni-
trile, 0.1% formic acid) to constitute a gradient elution.
Electrospray ionization was operated at the spray voltage
of 1.75 kV. Mass spectral data were extracted with the
MassHunter Quantitative Analysis package (Agilent Tech-
nologies, Inc., Santa Clara, CA USA) and peptides were
identified from MS/MS spectra with MASCOT (Matrix
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Science Inc., Boston, MA, USA). The MASCOT search
was performed with a peptide tolerance of 5 ppm and an
MS/MS tolerance of 0.05 Da, fixed modification with car-
bamidomethyl and variable methionine oxidation. Identifi-
cation of nontryptic fragments was performed manually
with an initial search on the basis of predicted peptide
masses of all possible fragments resulting from novel clea-
vage sites in the hinge region. The MS/MS spectra of sus-
pect peaks were verified by manual de novo peptide
sequencing to confirm their identities.
Patient samples
Individuals enrolled in the study protocol gave informed
consent and all procedures and the protocol were
reviewed and approved by the institutional review board
of the University of Texas Medical School at Houston.
Breast tumor tissue and adjacent normal tissues 2 cm
from the tumor sites were obtained from breast cancer
patients immediately following surgery by a certified
pathologist and were snap-frozen in liquid nitrogen
until analysis.
Detection of MMP expression in human breast cancer
tissues
MMP expression was measured using the Quantibody
reverse-phase human MMP array kit according to the
manufacturer’s instructions (RayBiotech, Norcross, GA,
USA). Fluorescence images were detected using a Gene-
Pix 4100A Scanner, and data were analyzed using the
QAH-MMP-1 GAL software based on the instruction
provided by the array manufacturer.
Statistical analysis
Where appropriate, statistical analysis was performed
using paired Student’s t test. P < 0.05 between treatment
groups is considered significantly different.
Results
Trastuzumab can be cleaved within the lower hinge in
vitro by human MMPs
An increased expression of human MMPs has been
reported in the tumor microenvironment of various cancer
types, including breast cancer [31]. To investigate whether
MMPs catalyze specific single hinge cleavage of trastuzu-
mab, a panel of four human MMPs were individually incu-
bated with trastuzumab in vitro, and hinge cleavage was
detected using a capillary electrophoresis separation sys-
tem. As shown in Figure 1A, trastuzumab was readily
cleaved at the hinge by all four MMPs tested, as indicated
by the production of scIgG-T. Based on previous studies
of other IgG1 antibodies [18,32], IdeS produced by Strepto-
coccus pyogenes can also cleave human IgGs at the hinge
region. We treated trastuzumab with IdeS and, as
expected, IdeS efficiently cleaved trastuzumab within the
hinge (Figure 1B). Since the solution-phase kinetics of IgG
single hinge cleavage by IdeS can be better controlled in
vitro compared with the human MMPs tested in this
study, the scIgG-T used for the in vitro characterization
and in vivo efficacy studies was prepared by incubating
trastuzumab with IdeS. The resultant scIgG-T was purified
as previously reported [18].
The purity of scIgG-T was analyzed by SDS-PAGE
separation under both nonreducing conditions (Figure 1C)
and reducing conditions (Figure 1D). Under nonreducing/
denaturing conditions, the intact trastuzumab was
detected as a single band of ~150 kDa. The IdeS scIgG-T
was detected as two major bands, with the upper band
representing the single hinge cleaved intermediate
(135 kDa band) and the lower band (~26 kDa) corre-
sponding to the detached Fc monomer (Fc(m)) in the dena-
turing conditions (Figure 1C). A faint band below 135 kDa
was visible and is most probably the (Fab)2 fragment that
migrates as a 110 kDa band by SDS-PAGE under nonre-
ducing conditions (Figure 1C). The proteolytic activity of
IdeS is quite active to cleave at the hinge of the first heavy
chain, but the hinge of the second heavy chain is relatively
resistant to the IdeS proteolytic cleavage. As a result, a
small fraction of the double-cleaved (Fab)2 fragment exists
in the scIgG-T preparation.
Under reducing/denaturing conditions, the intact tras-
tuzumab is separated into a heavy chain band (~50 kDa)
and a light chain band (~25 kDa) (Figure 1D, right lane),
whereas the IdeS single hinge cleavage of trastuzumab
resulted in four fragments: the ~50 kDa intact heavy
chain, the ~25 kDa light chain, and the two heavy chain
proteolytic cleavage fragments (Fc(m) and scHC) migrated
slightly above the light chain band (Figure 1D).
Sequence analysis of the tryptic digestion products of
scIgG-T using MS confirmed the IdeS cleavage site at
G236-/-G237 (Figure 2A). In comparison, the tryptic diges-
tion of intact trastuzumab showed only a hinge peptide
from T223 to K248 as expected (Figure 2B).
scIgG-T retains HER2 antigen engagement activity
To study the effect of single hinge cleavage on trastuzu-
mab HER2 binding and downstream signaling, we carried
out a series of in vitro experiments using purified scIgG-
T. The histograms collected from a flow cytometer for
the binding of trastuzumab and scIgG-T on BT474 high
HER2 expression breast cancer cells showed a concentra-
tion-dependent increase of the fluorescence signal
(Figure 3A). The concentration-dependent binding to
BT474 cells showed overlapping sigmoidal curves when
plotted with fluorescence signals against antibody con-
centrations, and the half-maximal effective concentration
values for trastuzumab and scIgG-T were 0.27 nM and
0.31 nM, respectively (Figure 3B). The effects of trastuzu-
mab and scIgG-T on HER2 signaling were detected by
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western blotting (Figure 3C). Similar to trastuzumab,
scIgG-T decreased phosphorylation of pHER2 (Y1248),
pAKT (S473) and pErk1/2 in BT474 cells (Figure 3C).
There were minimal effects on total HER2 levels by
either scIgG-T or the intact trastuzumab (Figure 3C).
Consistent with inhibition of pAKT (S473) and pErk1/2,
the intact trastuzumab and scIgG-T showed similar inhi-
bition of cancer cell proliferation (Figure 3D). Collec-
tively, these results indicated that a single cleavage of
trastuzumab within the lower hinge did not impact
Figure 1 Detection of trastuzumab proteolytic cleavage in vitro. (A) Capillary electropherograms (CEs) of trastuzumab and matrix
metalloproteinase (MMP)-digested trastuzumab under nonreducing and denatured running conditions. (B) CE of trastuzumab and IgG-degrading
enzyme S (IdeS)-digested single hinge cleaved trastuzumab (scIgG-T). (C) Purified scIgG-T under nonreducing and denaturing running conditions
and stained with Coomassie blue. (D) Trastuzumab and scIgG-T under reducing and denaturing running conditions and stained with Coomassie
blue. Fab, fragment antigen binding; Fc(m), Fc monomer; HC, heavy chain; LC, light chain.
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antibody binding to the HER2 antigen, inhibition of
downstream signaling, and inhibition of cell proliferation.
scIgG-T reduced binding to Fc gamma receptors and
diminished Fc-mediated ADCC activities
Fc gamma receptors (FcgRs) are expressed on diverse
immune cell types and are important for antibody engage-
ment of immune effector cell functions such as ADCC.
Binding of the intact trastuzumab and scIgG-T to ADCC-
activating receptors (FcgRI, FcgRIIA, and FcgRIIIA) was
assessed using ELISA. Intact trastuzumab demonstrated
binding to all three FcgRs in a concentration-dependent
manner (Figure 4A to 4C). In contrast, scIgG-T had
minimal binding to the FcgRIIA and FcgRIIIA receptors
(Figure 4B,C). Binding to the high-affinity FcgRI was also
reduced by scIgG-T, although the reduction was not
as marked when compared with FcgRIIA and FcgRIIIA
(Figure 4A). ADCC activities mediated by the intact
trastuzumab and scIgG-T were determined using human
PBMC as effector cells and the high HER2 expression
SKOV-3 ovarian cancer cells as target cells. Cancer cell
lysis mediated by the intact trastuzumab reached over 80%
at a concentration as low as 1 nM; however, cell lysis
induced by scIgG-T reached a 20% maximum at the same
concentration (Figure 4D). The decrease in ADCC activity
mediated by scIgG-T was consistent with its reduced bind-
ing affinity to FcgRs expressed on immune effector cells,
most notably the loss of binding to FcgRIIIa that is known
for its contribution to ADCC and is the main FcgR
expressed on NK cells.
scIgG-T had reduced anti-tumor efficacy in a mouse
xenograft tumor model
The impact of single hinge cleavage on trastuzumab effi-
cacy in vivo was determined by comparing tumor growth
inhibition by the intact trastuzumab and scIgG-T in a
Figure 2 Detection of single hinge cleaved trastuzumab and trastuzumab proteolytic cleavage using mass spectrometry. (A) Sequence
of the hinge region of trastuzumab showing the major trypsin cleavage sites (black arrows) and the IgG-degrading enzyme S (IdeS) cleavage
site (red arrow). Bottom graph: liquid chromatography (LC)/mass spectrometry (MS)/MS analysis of trypsin-treated single hinge cleaved
trastuzumab (scIgG-T), identifying the two peptides: THTCPPCPAPELLG and GPSVFLFPPKPK. Spectra are the MS2 spectra showing the b and y
ions for the two peptides, confirming their sequences. (B) Sequence of the hinge region of trastuzumab. Black arrows, major trypsin cleavage
sites. Bottom graph: LC/MS/MS analysis of trypsin-treated trastuzumab that identifies the peptide THTCPPCPAPELLGGPSVFLFPPKPK. Spectra are
the MS2 spectra showing the b and y ions for the peptide, confirming its sequence.
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mouse xenograft tumor model using high-HER2-expres-
sing BT474 breast cancer cells. The antibody was dosed
at 5 mg/kg and administered once weekly for 4 weeks
(Figure 5A). Compared with the isotype IgG control
groups, trastuzumab completely inhibited tumor growth
(Figure 5A). However, the scIgG-T-treated mice showed
significantly lower inhibition of tumor growth than that
of trastuzumab with a maximum of ~30% inhibition of
tumor growth when compared with the isotype control
IgG (Figure 5A). To understand the mechanism of tumor
growth inhibition by scIgG-T and trastuzumab, we con-
ducted ex vivo studies to investigate the effect of trastu-
zumab and scIgG-T on HER2-mediated downstream
signaling in xenograft tumors. Both intact trastuzumab
and scIgG-T-treated tumor extracts showed downregula-
tion of total HER2 levels, and inhibition of pHER2
(Y1248), pAKT(S473), and pErk1/2 when compared with
tumors treated with the isotype control (Figure 5B).
These results suggest that scIgG-T retained its HER2
antigen engagement and inhibitory effects on cancer cell
signaling.
scIgG-T reduced infiltration of immune effector cells in
the mouse xenograft tumor
To study whether scIgG-T lost Fc-mediated immune cell
effector function in vivo, we studied the effect of trastu-
zumab and scIgG-T on the infiltration of mouse immune
effector cells in the xenograft tumors. Mouse immune
cell infiltration was determined by immunohistochemis-
try using both anti-CD11b and F4/80 primary antibodies
that can recognize infiltrated mouse macrophages and
monocyte-derived immune cells. Trastuzumab-treated
tumor tissues showed infiltrated immune cells when
detected with both macrophage markers (Figure 6A,B).
Figure 3 Biological characterization of single hinge cleaved trastuzumab compared with the intact trastuzumab antibody in vitro. (A)
Histograms of trastuzumab and single hinge cleaved trastuzumab (scIgG-T) binding to HER2 expressed on BT474 cells using a flow cytometer.
(B) Concentration-dependent binding of trastuzumab and scIgG-T to HER2 expressed on BT474 breast cancer cells as measured by flow
cytometer. Mean fluorescence intensity (MFI) is plotted against each antibody concentration (nM) on the x axis. (C) Effect of trastuzumab and
scIgG-T on total HER2 expression, pHER2 (Y1289), pAKT (S473), and pErk1/2 in BT474 cells as determined by western blotting. (D) Inhibition of
BT474 breast cancer cell proliferation by trastuzumab and scIgG-T (n = 4). Percentage of cell growth inhibition calculated as: (fluorescence signal
of control group - signal of treatment group)/signal of control group×100.
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In contrast, tumor tissue treated with scIgG-T showed
much fewer numbers of mouse macrophage infiltration
and presented no difference from the tumor tissues trea-
ted with the isotype IgG control (Figure 6). Statistical
analysis of the number of immune cells detected in
tumor tissue slides in each group of three mice showed a
significant increase of infiltrated immune cells in the
intact trastuzumab-treated group (Figure 6, right bar
graph). The reduced immune cell infiltration in scIgG-T
treated tumors is consistent with the in vitro low ADCC
activity mediated by scIgG-T (Figure 4D). These results
imply that the decreased anti-tumor activity of scIgG-T
in vivo is the result of reduced ADCC-mediated by
immune effector cells.
Discussion
The correlation between accumulation of proteinases,
such as MMPs, in the tumor microenvironment and
cancer progression and metastasis is well documented
[31,33-37]. However, the role of MMPs in antibody hinge
cleavage and the consequence of such antibody cleavage
events in tumor microenvironment are unknown. Primary
and acquired resistance to cancer therapeutic monoclonal
antibodies such as trastuzumab in the clinic is one of the
major challenges in cancer therapy [10,38]. Mechanisms
resulting in refractory and acquired resistance to trastuzu-
mab are poorly understood, and different models have
been proposed including genetic mutations among key
genes in the HER signaling pathway such as phosphatase
and tensin homolog as well as upregulation of oncogenes
such as cMET, epidermal growth factor receptor and
HER3 [8,10,39]. The ability of MMPs to cleave IgG1 anti-
bodies specifically in the lower hinge region in vitro
suggests a possible link between MMP accumulation and
loss of antibody Fc-mediated immune effector function in
the tumor microenvironment. Using trastuzumab and
Figure 4 Trastuzumab and single hinge cleaved trastuzumab binding to Fcg receptors and antibody-dependent cellular cytotoxicity
activity. (A) Trastuzumab and single hinge cleaved trastuzumab (scIgG-T) binding to Fc gamma receptor (FcgR) I. (B) Trastuzumab and scIgG-T
binding to FcgRIIA. (C) Trastuzumab and scIgG-T binding to FcgRIIIA. (D) Antibody-dependent cellular cytotoxicity (ADCC) activity induced by
trastuzumab and scIgG-T using the high-HER2-expressing SKOV-3 ovarian cancer cells as target cells and human peripheral blood mononuclear
cells (PBMC) as effector cells (n = 3). Cell index was compared after treatment of trastuzumab and scIgG-T for 24 hours. Percentage of cell lysis
calculated as: (cell index of control group - cell index of treatment group)/cell index of control group×100. RFU, relative fluorescence units.
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high-HER2-expressing breast cancer cells, this study pro-
vided for the first time in vitro and in vivo experimental
evidence that proteinase cleavage of trastuzumab at the
lower hinge compromised its Fc-mediated immune effec-
tor functions such as ADCC in vitro, which resulted in
reduced anti-tumor efficacy in vivo. We used the bacterial
proteinase IdeS to prepare scIgG-T in our studies for two
reasons. First, IdeS cleaves the IgG1 antibody with high
specificity and generates a scIgG intermediate similar to
IgG1 cleavage products by human MMPs. Second, IdeS
cleaves the first strand rapidly and the second strand
slowly, which presents a practical window for the isolation
of homogeneous scIgG-T for in vitro and in vivo studies
[14,18,40].
In this study, trastuzumab was readily cleaved in vitro
by a panel of human MMPs (MMP-3, MMP-7, MMP-12,
and MMP-13), which was consistent with previous
reports that human IgG1 antibodies are susceptible to
proteinase cleavage [14,15,18,20,21,40]. However, MMPs
are complex proteinases and their proteolytic activities
are tightly regulated in vivo, and in vitro assays may not
reflect their in vivo activities [34]. It is noted that rela-
tively high levels of MMP9 and MMP3 in the patient
tumor sample were detected. Further studies are needed
to establish the specificity and activity of the MMPs in
the tumor microenvironment with respect to trastuzu-
mab hinge cleavage.
To carry out downstream experiments, we prepared a
large batch of scIgG-T by incubating trastuzumab with
IdeS, which cleaves the antibody at the G236-/-G237 site.
In comparison with trastuzumab, the IdeS-generated
scIgG-T showed comparable functions related to HER2-
mediated activities but exhibited reduced Fc-mediated
ADCC activity in vitro. A previous report demonstrated
that a single hinge cleaved IgG intermediate had a com-
plete loss of ADCC function in vitro [18], whereas the
scIgG-T tested in this study demonstrated significantly
reduced ADCC but not a complete loss of function. One
potential explanation for this discrepancy was that differ-
ent methods were used for ADCC detection. The ADCC
assay reported in this study was monitored over the
course of 120 hours, whereas the ADCC assay from the
previous report was carried out for 2 hours. Numerous
studies indicate that cell lysis in a 2-hour ADCC assay is
mediated by NK cells alone [41,42], and the only activat-
ing FcgR expressed by NK cells is FcgRIIIa [43]. The
complete loss of function seen in a 2-hour ADCC assay
is therefore consistent with the loss of binding to
FcgRIIIa. When ADCC assays are performed for time
periods exceeding 12 hours, myeloid linage cells can also
mediate in vitro ADCC [44]. The detection of ADCC
activity with scIgG-T in the present report, albeit at a
much reduced level relative to the intact version of IgG1,
perhaps reflects some degree of recruitment of myeloid-
mediated ADCC activity in addition to NK function. This
low level of ADCC activity is consistent with the ability
of scIgG-T to bind to the high-affinity FcgRI expressed in
the monocyte population.
The mechanisms of action for trastuzumab can be lar-
gely grouped into two categories: one is associated with
antagonizing HER2 signaling through Fab region of the
IgG1 molecule, and the other is through Fc-mediated
immune effector cell functions. The partial anti-tumor
efficacy conferred by scIgG-T in the mouse xenograft
model can be attributed to the direct HER2 engagement
by the Fab region of scIgG-T, as indicated by downregu-
lation of HER2 in tumor tissues and inhibition of pHER2
(Y1248), pAKT (S473), and pErk1/2. These results are
Figure 5 Trastuzumab and single hinge cleaved trastuzumab
tumor inhibition efficacy in breast cancer xenograft mouse
model. (A) BALB/c nu/nu mice (n = 5) were subcutaneously
inoculated with 5×106 BT474 human breast cancer cells. Mice were
treated with the antibodies at 5 mg/kg weekly for a total of five
doses when tumors reached an average size of 100 mm3. Tumor
sizes were measured and compared among the treatment groups.
*P < 0.05 and **P < 0.005. (B) Tumor lysates were prepared from
the frozen xenograft tumor tissues. Total HER2 expression, pHER2
(Y1248), pAKT (S473), and pErk1/2 were determined by western
blotting. scIgG-T, single hinge cleaved trastuzumab.
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consistent with previous findings that trastuzumab
mechanisms of action include inhibition of HER2 down-
stream signaling [8,39,45] and downregulation of HER2
receptor level [46].
Because scIgG-T showed diminished Fc-mediated
ADCC in vitro, it is expected that scIgG-T will be less
effective in engaging immune cell-mediated cancer cell
killing in vivo. As an IgG1 isotype antibody, trastuzumab
mediates ADCC by recruiting immune effector cells to
HER2-overexpressing tumor cells [25]. Xenograft studies
in FcgR knockout mice showed that interaction with the
ADCC activation receptor (FcgRIII) is essential for
the efficacy of trastuzumab [3]. Patients with the higher
binding affinity FcgRIIIa-158V/V genotype showed an
improved response to trastuzumab than patients with the
lower affinity FcgRIIIa-158 F/F and F/V genotypes, again
suggesting that Fc-mediated effector function plays a key
role in the clinical efficacy of trastuzumab [4]. Even
though the correlation between FcgRIIIa polymorphisms
and outcome in trastuzumab-treated cancer patients was
not confirmed in a recent clinical study [47], the impor-
tant role of FcgRIIIa in Fc-mediated immune function is
not in dispute. The reduced anti-tumor efficacy by
scIgG-T strongly supports that Fc-mediated effector
function is a key mechanism of action for in vivo efficacy
of trastuzumab. The significantly reduced immune cell
infiltration shown in scIgG-T-treated mouse xenograft
tumor as compared with that treated with intact trastu-
zumab again supports the notion that scIgG-T has com-
promised Fc effector function due to lack of engagement
of immune cells at the tumor site. Mouse macrophages
are phagocytic and express CD11b and F4/80 [48].
Macrophage recruitment to the tumor site has been
documented in a PyMT mouse breast cancer model
[48,49]. Even though the nude mouse used in the xeno-
graft tumor model is believed devoid of T cells, the
results in the present study clearly indicate that mono-
cyte-derived immune cell infiltration to tumor tissue
occurs in the nude mouse tumor model when treated
with trastuzumab. The association of reduced anti-tumor
efficacy by scIgG-T with the decreased number of infil-
trated immune cells further suggests that infiltrated
mouse immune cells in xenograft tumor tissue are cap-
able of mediating anti-tumor activities when high HER2
Figure 6 Immune cell infiltration in xenograft tumors measured by immunohistochemistry. Mouse xenograft tumors treated with
trastuzumab, single hinge cleaved trastuzumab (scIgG-T), and the isotype control were fixed in 4% paraformaldehyde. Six immunohistochemistry
slides were prepared from the paraffin-embedded tissues of two mice from each treatment group. Monocytes/macrophages were stained using
the anti-mouse integrin aM/CD11b and anti-mouse F4/80 antibodies. (A) Representative images (×40) of CD11b-stained tumor tissue and
positive-stained immune cells indicated by black arrows. Right bar graph: average number of CD11b-positive cells per tumor tissue slide (n = 6).
Pairwise t test used to compare different treatment groups. **P < 0.005. (B) Representative images (×40) of F4/80-stained tumor tissues from
different treatment groups. Right bar graph: Average number of positive stained cells detected per tissue slides (n = 6). Pairwise t test used to
compare different treatment groups. **P < 0.005.
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expression cancer cells are treated with trastuzumab.
This finding is consistent with previous reports on the
correlation of immune effector cell infiltration and tras-
tuzumab efficacy in the clinic [24,25].
This study showed that trastuzumab can be readily
cleaved by MMPs in the lower hinge in vitro and that
scIgG-T showed much reduced anti-tumor efficacy in
comparison with the intact trastuzumab in vivo. Further
investigation is necessary to determine whether the hinge
cleavage of trastuzumab occurs in the tumor microenvir-
onment in the clinical setting. It is interesting to note
that a patient who was diagnosed with HER2-overexpres-
sing breast cancer and was under adjuvant treatment
with trastuzumab and chemotherapy for 6 months
showed evidence of hinge cleavage of trastuzumab in the
tumor tissue (Figure 7A). More importantly, single hinge
cleavage of trastuzumab was detected in the tumor tissue
but was not visible in the plasma sample where other
host IgG antibody is abundant (Figure 7A). Expression of
MMPs (MMP-1, MMP-2, MMP-3, MMP-8, MMP-9,
MMP-10, and MMP-13) was also analyzed using a
reverse-phase protein array. Among the seven MMPs
tested, both MMP-3 and MMP-9 were elevated in sam-
ples from the tumor site when compared with that from
the adjacent normal tissues (Figure 7B).
While the extent of the hinge cleavage of trastuzumab
in cancer patients during the antibody treatment is yet to
be established in more patient samples, our data demon-
strated that the cleavage of trastuzumab and generation
of scIgG-T can occur in the tumor microenvironment.
Furthermore, we hypothesize that hinge cleavage from
trastuzumab to scIgG-T in the tumor microenvironment
may lead to reduced anti-tumor efficacy by weakening
the antibody Fc interaction with immune effector cells.
However, the extent of the hinge cleavage of trastuzumab
in breast cancer patients is yet to be established in a large
patient cohort. Further investigation in clinical settings is
warranted to determine whether single hinge cleavage
represents a novel mechanism for cancer cells to invade
immune functions mediated by trastuzumab in vivo.
Conclusion
Studies of resistance mechanisms of trastuzumab have
been focused on genetic mutations in the HER2 signaling
pathways and little is known on the role of immune eva-
sion in the development of trastuzumab resistance. This
study demonstrated that trastuzumab can be cleaved by
MMPs within the lower hinge and that the hinge cleaved
trastuzumab (scIgG-T) showed a significantly reduced
anti-tumor efficacy due to the weakened immune effector
function, including ADCC. Taken together, the results in
this study suggest that hinge cleavage from intact trastuzu-
mab to scIgG-T in the tumor microenvironment may lead
to reduced anti-tumor efficacy by weakening the antibody’s
ability to mediate immune effector functions. Further stu-
dies are warranted to understand the significance of single
hinge cleavage on trastuzumab efficacy in the clinic.
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